Encouraging Additional Vaccinations for Immunocompromised Advised
The JAMA Network Open recently published an Original Investigation that found 41% of adults with impaired immune systems had received a 4th mRNA vaccine dose.
However, only 1% had received their recommended 5th dose
'Our results highlight a substantial gap in adherence to recommendations for mRNA monovalent COVID-19 booster doses,' wrote these researchers on January 20, 2023.
"Given the increased risk for severe COVID-19 in this vulnerable population and the well-established additional protection afforded by booster doses, targeted and tailored efforts to ensure that immunocompromised individuals remain up to date with COVID-19 booster dose recommendations are warranted," the researchers added.
Immunocompromised individuals (i.e., persons with immunocompromising conditions or who are taking immunosuppressive medications) often mount weaker immune responses to vaccines and experience higher rates of vaccine failure compared with immunocompetent individuals.
As of January 2023, both the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have progressively amended COVID-19 vaccine authorizations and recommendations to include additional COVID-19 vaccine doses for immunocompromised individuals.
Disclosures: Pfizer, a company producing mRNA vaccines, sponsored his study. Corresponding Author: Sara Y. Tartof, Ph.D., MPH, Department of Research and Evaluation, Kaiser Permanente Southern California ([email protected]).